Day: December 8, 2025

RICHARDSON, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) — Mavenir, the software company building AI-by-design mobile networks, today announced a strong leadership team to accelerate its vision for telco-first, cloud-native, AI-by-design networks. This transformation follows the company’s recent recapitalization and aligns with a refreshed product strategy focused on mobile core, AI-enabled automation, and cloud-native platforms. New … Read more

Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy Leave a reply RICHARDSON, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) — Mavenir, the software company building AI-by-design mobile networks, today announced a strong leadership team to accelerate its vision for telco-first, cloud-native, AI-by-design networks. This transformation … Read more

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12) After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, … Read more

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks Leave a reply REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks … Read more

Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober VICTORIA, Seychelles, Dec. 08, 2025 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), today released its October 2025 Protection Fund report, recording an average monthly valuation of $741,435,710 despite a challenging month across … Read more

Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober Leave a reply Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober VICTORIA, Seychelles, Dec. 08, 2025 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), today released its October 2025 Protection Fund … Read more

Recognition follows a vote by professional and active traders, highlighting the critical role of execution quality in institutional-grade trading Best Broker for Execution at the Professional Trader Awards 2025 – EBC Financial Group Christopher Potts, Chief Operating Officer & Chief Technology Officer, EBC Financial Group (UK) Ltd, representing EBC Financial Group to receive the Best … Read more

EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025 Leave a reply Recognition follows a vote by professional and active traders, highlighting the critical role of execution quality in institutional-grade trading Best Broker for Execution at the Professional Trader Awards 2025 – EBC Financial Group Christopher Potts, Chief Operating Officer … Read more

LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — A sharp acceleration in global wealth migration in 2025 is colliding with rapidly diverging private healthcare costs worldwide, making the availability and costs of reliable private care a decisive factor in where high-net-worth families choose to live, invest, and secure residence or citizenship rights. New client data released … Read more

Private Healthcare Costs Are Rewriting the Map for Migrating Millionaires, New Data Shows Leave a reply LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — A sharp acceleration in global wealth migration in 2025 is colliding with rapidly diverging private healthcare costs worldwide, making the availability and costs of reliable private care a decisive factor in where … Read more

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease features A 12-day manufacturing time resulted in a vein-to-vein time … Read more

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting Leave a reply DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated … Read more